EIT Pharma

USAKirklandBiotech & PharmaSeries A

Overview

Where EIT Pharma is now

EIT Pharma announced a Series A round of $35M on 31 August 2026, led by Propel Bio Partners.

Observed Described in the funding announcement as "biotechnology company focused on developing therapies for infectious diseases". Source

Latest round
Series A
Amount
$35M
Announced
31 August 2026
Headquarters
Kirkland, USA
Sector
Biotech & Pharma
Investors
Propel Bio Partners
Also participating
Good Ventures, Arrowtown, and others
Relevant leadership
CEO Dr

What happens next

What this raise plausibly creates

AfterRaise inferenceInferred

Likely next Moves

  • Accelerated hiring across functions
  • Repeatable go-to-market build
  • First senior commercial hires

Opportunities this could create

  • Clinical operations
  • Regulatory affairs
  • CMC and manufacturing
  • Quality systems
  • Medical affairs

Based on the Biotech & Pharma sector and a Series A round. Not a statement of fact.

Early momentum1 connected signal
  • 31 August 2026$35M Series A announced

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Momentum Inferred

AfterRaise Score

71
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
16/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Growth timeline

What has happened so far

  • 31 August 2026
    $35M Series A
    Led by Propel Bio Partners.

Observed The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

Moves

Published by the company

Share a Move

No company-published Moves yet

AfterRaise has the funding facts for EIT Pharma from public sources. What it does not have is what the company is doing next, in the company's own words. That part only they can write.

Work here? Publish the first Move

Opportunities

Work this company has opened

No open Opportunities listed

Jobs, projects, partnerships and advisory needs appear here once the company has claimed its room and published them.

Work here? Open the first one

Open to

Who may approach EIT Pharma

Not yet specified

EIT Pharma has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Work here?

Own your growth story.

This room belongs to EIT Pharma. Claim it to tell people where you are going, confirm or correct what AfterRaise noticed, publish Moves, ask the network, control who can contact you, and share your growth story. Everything you publish is reviewed before it appears.

Also moving

Other Biotech & Pharma companies

See the sector